Papers

39

Total Citations

2,531

H-Index

22

About

Alon Z. Weizer is a prominent urologic oncologist whose research has profoundly shaped the field of minimally invasive and robotic surgery for urological cancers, particularly bladder cancer and renal tumors. He is perhaps best known as a principal investigator of the landmark RAZOR trial, a randomized phase 3 study comparing robot-assisted to open radical cystectomy in bladder cancer patients, which has garnered over 760 citations since its 2018 publication and established robotic cystectomy as oncologically non-inferior to the traditional open approach. His subsequent three-year follow-up analysis further solidified these findings, influencing surgical decision-making worldwide. Through his leadership within the International Robotic Cystectomy Consortium, Weizer has contributed critical multi-institutional data on urinary diversion techniques and complication profiles following robotic cystectomy. Beyond bladder cancer, his work extends to robotic retroperitoneal lymph node dissection for testicular cancer and minimally invasive partial nephrectomy, including investigations of the RENAL nephrometry scoring system. With a body of work exceeding 1,600 citations across his most impactful studies, Weizer stands as a driving force in advancing evidence-based, minimally invasive urologic oncology.

Research Focus

Key Achievements

22
H-Index
39
Papers
2,531
Total Citations
65
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
760 citations · 2018
📈 Most Prolific Year: 2013 (8 Papers)
🤝 Key Collaborators: 196
🏛 Institutions: University of Michigan–Ann Arbor, Michigan Medicine, Ann Arbor Center for Independent Living

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago